Skip to content
Sign in

ERNA · NASDAQ

Ernexa Therapeutics (ERNA) Stock Price & Fundamentals

$1,301.72−0.07%−$0.94End-of-day price as of Oct 9, 2026

Ernexa Therapeutics (ERNA) closed at $1,301.72 on Oct 9, 2026, down 0.07% from the previous close of $1,302.66.

Share price, past year

1Y +41.47%

52-week range $885.13 – $1,314.32. Daily closing prices.
Monthly closing prices
Last closing price of each month
DateClose
Oct 9, 2026$1,301.72
Sep 30, 2026$1,312.80
Aug 31, 2026$1,212.16
Jul 31, 2026$1,228.82
Jun 30, 2026$1,169.11
May 29, 2026$1,091.70
Apr 30, 2026$1,099.71
Mar 31, 2026$1,061.99
Feb 27, 2026$999.50
Jan 30, 2026$956.66
Dec 31, 2025$925.93
Nov 28, 2025$901.75
Oct 31, 2025$940.57

Key statistics

Market cap
$1.52B
P/E (TTM)
21.6
EPS (TTM)
$60.36
Revenue (TTM)
—
Net income (TTM)
−$12.26M
Shares outstanding
1.2M
Dividend yield
—
52-week range
$885.13 – $1,314.32

Ernexa Therapeutics's market cap is $1.52B, based on a share price of $1,301.72 and 1.2M shares outstanding as of Jun 30, 2026.

Financials

Ernexa Therapeutics reported revenue of $582.00K for fiscal 2024, up 755.88% from fiscal 2023.

Ernexa Therapeutics reported a net loss of $14.08M in fiscal 2025.

Annual revenue

FY14FY15FY16FY17FY18FY19FY20FY22FY23FY24
Annual revenue by fiscal year; the table below lists the values.
Ernexa Therapeutics annual financials by fiscal year, from SEC filings
Fiscal yearRevenueGrowthNet incomeNet marginEPS (diluted)Free cash flow
FY2024ended Dec 31, 2024$582.00K+755.9%−$44.54M−7,652.8%−$48.96−$16.21M
FY2023ended Dec 31, 2023$68.00K—−$21.67M−31,864.7%−$4.08−$20.43M
FY2022ended Dec 31, 2022$0.00−100.0%−$24.58M—−$8.06−$21.27M
FY2020ended Dec 31, 2020$5.80M−70.7%−$7.29M−125.7%−$8.20−$8.14M
FY2019ended Dec 31, 2019$19.81M−15.1%−$2.05M−10.3%−$14.40$2.62M
FY2018ended Dec 31, 2018$23.34M+9.7%−$259.00K−1.1%−$2.00$717.00K
FY2017ended Dec 31, 2017$21.27M−4.7%−$1.08M−5.1%−$9.00−$179.00K
FY2016ended Dec 31, 2016$22.31M−9.0%−$2.92M−13.1%−$30.80−$404.00K
FY2015ended Dec 31, 2015$24.52M−5.9%————
FY2014ended Dec 31, 2014$26.05M—————
Ernexa Therapeutics quarterly results
QuarterRevenueNet incomeEPS (diluted)
Q4 FY2024ended Dec 31, 2024$1.00K−$5.76M$41.31
Q3 FY2024ended Sep 30, 2024$487.00K−$26.60M−$73.70
Q2 FY2024ended Jun 30, 2024$47.00K——
Q1 FY2024ended Mar 31, 2024$47.00K——
Q3 FY2023ended Sep 30, 2023$51.00K——
Q1 FY2023ended Mar 31, 2023$0.00——
Q3 FY2022ended Sep 30, 2022$0.00——
Q4 FY2020ended Dec 31, 2020$1.18M——

Company profile

Name
Ernexa Therapeutics Inc.
Ticker
ERNA
Exchange
NASDAQ
Industry (SEC SIC)
Pharmaceutical Preparations
Headquarters
1035 Cambridge Street, Suite 18a, Cambridge, MA 02141
Incorporated in
DE
Fiscal year ends
December
SEC CIK
0000748592

Recent SEC filings

Frequently asked questions

What is Ernexa Therapeutics's stock price?

Ernexa Therapeutics (ERNA) closed at $1,301.72 on Oct 9, 2026, down 0.07% from the previous close of $1,302.66.

What is Ernexa Therapeutics's market cap?

Ernexa Therapeutics's market cap is $1.52B, based on a share price of $1,301.72 and 1.2M shares outstanding as of Jun 30, 2026.

How much revenue does Ernexa Therapeutics make?

Ernexa Therapeutics reported revenue of $582.00K for fiscal 2024, up 755.88% from fiscal 2023.

What is ERNA's P/E ratio?

Ernexa Therapeutics's price-to-earnings ratio is 21.6, based on trailing twelve-month diluted EPS of $60.36.

Does Ernexa Therapeutics pay a dividend?

Ernexa Therapeutics's recent filings report no dividends declared over the last four quarters.

Sources and methodology

Fundamentals come from Ernexa Therapeutics Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures